Why the study?
Many patients fail to achieve ideal LDL-C goals with statins alone, and previous literature on ezetimibe plus statins focused only on coronary heart disease rather than all ASVD subtypes.
Does ezetimibe plus statins improve LDL-C reduction and safety in elderly patients with atherosclerotic vascular disease compared to statins alone?
Does ezetimibe plus statins improve LDL-C reduction and safety in elderly patients with atherosclerotic vascular disease compared to statins alone?
Ezetimibe plus statins may provide an important therapeutic option for LDL-C reduction in elderly patients with multi-organ atherosclerosis.
Answers are grounded in this paper and cite their sources.
Ezetimibe addition to statins may aid LDL-C goals in elderly ASVD; leaves open whether outcomes improve.
It is well known that atherosclerotic vascular disease (ASVD) in the elderly is a global disease with high morbidity, mortality and disability, and plasma LDL-C correction is the most important strategy for ASVD control. However, a large proportion of patients failed to achieve their ideal LDL-C goals after statins use. Ezetimibe, a newly non-statin lipid-lowering agent, is an inhibitor of exogenous cholesterol absorption. Whereby, ezetimibe plus statins may reduce LDL-C more strongly than statins alone. Differed from any other papers published previously, which only involved ezetimibe plus statins for coronary heart disease, the highlight of this paper is to summarize the efficacy and safety of ezetimibe plus statins in all kinds of ASVD subtypes and their related diseases, mainly included aortic atherosclerosis, coronary artery disease, cerebrovascular and peripheral artery diseases. Obviously, this paper is inimitable, which will provide the readers an important reference, especially in treating the elderly with multi-organs atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Wan et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: